Conference Day Two
8:55 am Chair’s Opening Remarks
Discovering the Latest Preclinical & In-Human Advancements in Inflammasome Targeting to Transfer Key Learnings & Confidently Move Towards the Clinic
9:00 am NLRP3 Inhibitor to Treat Neuroinflammatory & Neurodegenerative Diseases: From Discovery to Development
Synopsis
Session Overview to Be Confirmed
9:30 am Exploring the Development of RRx-001: the NLRP3 Small Molecule Inhibitor for a Variety of Inflammatory Diseases
Synopsis
- Understanding the mechanism of action and preclinical data for the therapeutic candidate
- Highlighting key formulation and delivery considerations to be on-target and measuring off-target effects
- Identifying the next steps for the therapeutic candidate
Humanized Mouse Models & Innovative Preclinical Models for Inflammasome Therapeutic Translational Success
10:00 am Novel Potent, Selective, & Brain Penetrant NLRP3 Inhibitors Mitigate Neuroinflammation in Preclinical Models
Synopsis
- Highlighting the potent NLRP3 inflammasome inhibitor
- Showcasing optimization of brain exposure
- Demonstrating efficacy in mouse models of human disease and target engagement in the central nervous system
10:30 am Morning Break & Networking
11:00 am Discovery of Novel & Potent Inhibitors Targeting the NLRP3 Pathway
Synopsis
- Using the physic-based computational platform, allied with machine learning techniques to enable the identification of NLRP3 inhibitors
- Highlighting the inhibitor’s capability to target both peripheral and CNS diseases
- Harnessing a range of functional and mechanistic cellular assays, in vivo pharmacodynamic and disease models to explore pathway inhibition
11:30 am Anti-ASC Antibodies: A Promising Approach for Dual Targeting of Protein Aggregation & Inflammation
Synopsis
- Development and characterization of monoclonal antibodies targeting ASC
- In vitro efficacy in protein aggregation and inflammation assay
- In vivo target engagement and efficacy in a model of Amyloidosis
Getting to the Target: Formulation & Delivery Considerations for Inflammatory Diseases
12:00 pm Specifically Targeting & Avoiding Off-Target Effects: Identification of Novel, Highly Potent, CNS Penetrant NLRP3-Specific Inhibitors
Synopsis
- Revealing NLRP3 levels rise with age and are positively correlated with all-cause mortality and cognitive decline
- Functionally inhibiting NLRP3 inflammasome in vivo and in vitro with comparable or superior potency relative to publicly known inhibitors
- Identifying molecules that allow favorable oral bio-availability and blood-brain barrier penetration
12:30 pm Lunch & Networking
Deciphering the Upstream Activation Mechanisms of Inflammasomes to Understand Regulatory Factors of Inflammation for Therapeutic Targeting
1:30 pm Targeting Inflammasomes Through Other Mechanisms: The Role of Innate Immune Sensors in the Regulation of Inflammasomes
Synopsis
- Regulating Inflammasome activation via P2X7 and adenylate cyclase
- Exploring GPCR19 agonism inhibits both the priming phase and the activation phase of the inflammasome
- Highlighting the promising therapeutic approach for inflammatory diseases, such as atopy dermatitis, Alzheimer’s disease, and infection disease
Assessing Downstream Targets of the Inflammasome Pathway & Pathway Cross-Talks to Complete the Picture for Effective Targeting
2:00 pm Identifying Cell-Death Pathway & Inflammasome Pathway Cross-Talk As Contributing Drivers to Cell Death
Synopsis
- Deliberating how useful it is to target pyroptosis and apoptosis in inflammatory diseases
2:30 pm Exploring Inflammasome-Activated Gasdermin Triggering Pyroptosis to Hone Therapeutic Development
Synopsis
- Discovering novel Gasdermin-D inhibitors
- Highlighting the functional effect of inhibitors
Focusing Inflammasome Therapeutic Development to Accelerate the Field to the Clinic
3:00 pm Roundtable: From Discovery to Preclinical Development to the Clinic: Addressing the Key Next Steps to Take as A Field to Supercharge Inflammasome Therapeutics to the Patient
Synopsis
- Discovery & Novel Inhibitors/Activators: Should the focus be on NLRP3? What are the benefits of looking to other targets? What are the upstream and downstream considerations in the pathway?
- Preclinical Development: Should we look to animal models or focus on the development of novel models? What disease applications should be the go-to?
- Bridging the Gap: Translational Considerations Where do we go for biomarker development whilst we wait for clinical readouts?
- Looking to the Clinic Which patient population will inflammasome therapeutics have the greatest benefit? What should be considered for dose and targeting?
3:30 pm Panel Discussion: Assessing the Current Landscape of Inflammasome Therapeutics to Identify the Bottlenecks, Key Field Considerations, & Debating the Future of Inhibitors/Activators
Synopsis
- Looking outside of NLRP3: Which inflammasome do we think is going to be the next go-to? And will it be disease-specific?
- Exploring upstream targets of inflammatory processes:
- Diving into downstream targets of inflammasome activation to complete the picture:
- Understanding the key limitations of preclinical models to move forward: Which models do big pharma want to see inflammasome data in?
- Harnessing novel humanized preclinical models: Which models do we think will be effective and well adopted by the field?
- Navigating measuring target engagement and patient selection: What should we explore for inflammasome biomarkers?